Uptake of Lung Cancer Screening May Depend on Making Testing Fast and Convenient

Published Apr 22, 2020

Data from Australia Offers Useful Guidance for Similar Conditions in Other Advanced Economies

Value in HealthLawrenceville, NJ, USA—April 22, 2020—Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of new research showing that uptake of lung cancer screening may depend on making testing fast and convenient. The report, “Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment,” was published in the April 2020 issue of Value in Health.

Globally, lung cancer is the most common cause of cancer death, with nearly 1 in every 5 cancer deaths attributed to the disease. Diagnosing lung cancer at an early stage, when treatment is more effective, is key to reducing morbidity and mortality. Low-dose computerized tomography screening reduces lung cancer mortality by at least 20%. However, as the new study by Norman, et al illustrates, it is important to identify what aspects of low-dose computerized tomography lung cancer screening are either attractive or unattractive to people because these characteristics determine a patient’s underlying willingness to be screened.

“To explore Australian population preferences for lung cancer screening, we used a ranking task administered online,” said author Richard Norman, PhD, School of Public Health, Curtin University, Perth, Australia. “Respondents were presented with 3 options: 2 hypothetical screening alternatives or ‘no screen.’ The aim of the project was to identify what aspects of low-dose computerized tomography lung cancer screening are relatively more or less attractive to individuals most likely to be targeted for screening.”

The results show that when choosing between different lung screening approaches, the average respondent placed emphasis on the type of screen, distance from home, speed of results, radiation exposure, and cost. When survey respondents were divided into those with lower or higher risk, the groups diverged in how they considered time spent at the location (the high-risk respondents were sensitive to this) and potentially the distance traveled to the facility, the speed of results, and the radiation exposure.

When considering the drivers of opting out of any screening, it was clear that opting out was predicted by respondent characteristics, particularly sex, age, education, smoking history, and whether the respondent had a previous cancer diagnosis.

“The results of this study show if the intent is to change the uptake of lung cancer screening, then focusing on providing fast and convenient testing is an important avenue for doing so,” said Dr Norman. “Respondents at higher risk appear to be less willing to travel significant distances and less willing to spend time at the location.”

###

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2018 impact factor score is 5.037. Value in Health is ranked 5th of 98 journals in healthcare sciences and services, 4th of 81 journals in health policy and services, and 11th of 363 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Website  | Twitter (@isporjournals)

Related Stories

Moving Precision Medicine From Evaluation Into Practice and Policy

May 26, 2020

Value in Health announced the publication of a series of articles focused on methods for moving from the evaluation of precision medicine into practice and policy.

Is There a Future for Biopharmaceutical Value-Based Contracting?

Apr 22, 2020

Value in Health announced the publication of a series of articles providing perspectives on biopharmaceutical value-based contracting and what the future may hold for risk-sharing arrangements.

Incorporating Patients’ Perspectives in the Medical Device Regulatory Process

Apr 8, 2020

Value in Health announced the publication of an article highlighting US Food and Drug Administration (FDA) guidance and lessons learned regarding the use of patient preference information for FDA decision making about medical devices
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×